TRIAL DETAIL

A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable

Drug:
Trial Name:
A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable
NCT#:
Conditions:
Solid Tumors
Status:
Ongoing, but not recruiting
Phase:
1
Start Date 03/01/2008
Age of Trial (yrs) 16.2
Treatment Phase:
Gleevec-resistant
Drug Category:
PI3K inhibitor
Strategy:
Block KIT Signal Path
Trial Type:
GIST not specified. GIST patient enrollment unknown.
Other Protocol IDs:
GDC4254g
Sponsor:
Genentech, Inc.
Patient Contact:
See site contact info below
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Oral
Trial Notes:
This is phase 1 study to test the safety, tolerability and pharmacokinetics of GDC-0941. GDC-0941 is a PI3K inhibitor.
Targeting signals downstream from KIT and PDGFRA is one strategy being investigated for Gleevec-resistant GIST and for many cancers in general. One of the most promising downstream targets appears to be PI3K.
This drug was initially developed by Piramed in the United Kingdom. GDC-0941 selectivity has not yet been published, so this information is unknown. We have been told informally that this oral drug inhibits multiple class I PI3K’s.

Trial Links
 

Trial Results
 
 

Drug Information
The identification of GDC-0941
 
Pharmacokinetics and pharmacodynamic biomarkers for the pan-PI3K inhibitor GDC-0941: Initial Phase I evaluation
 

Trial Sites

Name
Address
City
State
Zip
Country
Surrey
sM2 5PT
UK